Multiple Sclerosis Newswire (Page 10)

Multiple Sclerosis Newswire (Page 10)

Comprehensive Real-Time News Feed for Multiple Sclerosis. (Page 10)

Results 181 - 200 of 92,667 in Multiple Sclerosis

  1. Setting table for those in needRead the original story w/Photo

    Saturday Jul 25 | Sentinel & Enterprise

    A nonprofit agency that provides meals to the critically and chronically ill has expanded its service to include the Twin Cities. "We are excited to bring medically tailored meals to the communities of Fitchburg and Leominster," said David Waters, CEO of Community Services, a Jamaica Plains-based agency that provides meals to those suffering from HIV/AIDS, cancer, diabetes, multiple sclerosis, Lou Gehrig's disease and more than 30 other chronic ailments.

    Comment?

  2. Letter: Parking, aesthetic sidewalk beauty, green spaceRead the original story w/Photo

    Saturday Jul 25 | The Daily Record

    My wife and I had a wheelchair friendly house built on the north end of Wooster 17 years ago. My incurable multiple sclerosis took away my walking capabilities 20 years ago.

    Comment?

  3. Why there's no bubble in biotechRead the original story w/Photo

    Saturday Jul 25 | Canada.com

    ... demonstrates. The company slashed its outlook due to disappointing sales growth for Tecfidera, its key multiple sclerosis drug. Aside from company-specific risks such as weak demand, investors must keep a close eye on key product approvals, drug ...

    Comment?

  4. Charting the MarketRead the original story w/Photo

    Saturday Jul 25 | Barron's

    Strong North American sales and growth in cloud-computing services lifted the e-tailer's June-quarter revenues 20%, to $23 billion, and yielded a surprise profit. After an FDA meeting, the drug developer said it will start final Phase 3 clinical trials this year for its novel glaucoma treatment, aiming for results in 2016.

    Comment?

  5. Bloomberg View: Medical marijuana research needs support of CongressRead the original story w/Photo

    Friday Jul 24 | Watertown Daily Times

    ... disorders and Tourette's Syndrome. It did better in treating chronic pain and spasticity arising from multiple sclerosis. Yet states have adopted laws that allow the drug to be used to treat everything from anxiety to writer's cramp. One medical ...

    Comment?

  6. Bitter pill for Biogen stockRead the original story

    Friday Jul 24 | Boston Herald

    ... to 16 percent. Revenue on every major drug missed analysts' expectations, including their drugs for multiple sclerosis. "We obviously have a lot of work ahead of us as we strive to maximize the success of our commercial business and execute on our ...

    Comment?

  7. Multiple Sclerosis: Top 10 Treatment CentersRead the original story w/Photo

    Friday Jul 24 | News Max

    There are a variety of treatment options available for treating multiple sclerosis. Among the numerous reputed treatment centers in the U.S., the leading ten facilities are:.

    Comment?

  8. India granted patent to treat incurable disease in MalaysiaRead the original story

    Friday Jul 24 | Newkerala.com

    ... Mediworld has treated over 1300 patients from 51 countries. Conditions treated include spinal injuries, multiple sclerosis, Parkinsons disease, diabetes, Lyme disease, cerebral palsy and autism. A number of peer-reviewed papers related to this ...

    Comment?

  9. Youth group leaves for South Dakota mission tripRead the original story w/Photo

    Friday Jul 24 | Fort Morgan Times

    ... youth group spent a week in Alamosa, painting and repairing houses for an elderly couple and a woman with multiple sclerosis. Nine people went on that trip, which was for middle school as well as high school students. This year's trip is only for ...

    Comment?

  10. Stocks end week with a thudRead the original story w/Photo

    Friday Jul 24 | Reuters

    ... On the earnings front: Biogen slashed its 2015 forecasts because of disappointing sales of its flagship multiple sclerosis drug. Its stock was the day's biggest loser on the S&P 500. The S&P's biggest winner: Amazon. Analysts raced to hike their ...

    Comment?

  11. Biogen shares plunge 22% after outlook slashedRead the original story w/Photo

    Friday Jul 24 | MarketWatch

    ... outlook to lower demand for Tecfidera, which has become one of the most commonly used treatments for multiple sclerosis since it came on the market in 2013, and is the company's biggest product by revenue. Fewer new patients are being prescribed the ...

    Comment?

  12. Visa, Amazon, Starbucks, Biogen and Pandora are big market moversRead the original story w/Photo

    Friday Jul 24 | The Winnipeg Free Press

    ... expectations. The biotechnology company cut its full-year adjusted profit forecast as sales of one of its multiple sclerosis drugs slow down. The world's largest airline reported strong second-quarter profit but warned a key revenue figure will ...

    Comment?

  13. Africa: Tpp Negotiators Must Fix the Most Damaging Trade Agreement Ever for Global HealthRead the original story w/Photo

    Friday Jul 24 | AllAfrica.com

    ... for biologic medicines, which include vaccines and drugs to treat conditions such as cancer and multiple sclerosis. Data exclusivity blocks government regulatory authorities from allowing price-lowering generic competitors to enter the market with ...

    Comment?

  14. Visa and Amazon are big market moversRead the original story w/Photo

    Friday Jul 24 | SFGate

    The payment processing company's third-quarter profit jumped 25 percent, helped by a double-digit rise in activity on its network. The biotechnology company cut its full-year adjusted profit forecast as sales of one of its multiple sclerosis drugs slow down.

    Comment?

  15. With $4,000 a month, sister feeds Nairobi's destitute, disabled elderlyRead the original story w/Photo

    Friday Jul 24 | National Catholic Reporter

    ... they have family far away that has disowned them. Everyone is elderly except for one young man who has multiple sclerosis, and his mother threw him out of the house. We also have four orphans, which we're not supposed to since we have no space, but ...

    Comment?

  16. Does Concussion Impact Men and Women Differently?Read the original story

    Friday Jul 24 | Newswise

    ... and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy. For more information about the American Academy of Neurology, visit ...

    Comment?

  17. CommentsRead the original story w/Photo

    Friday Jul 24 | Religion News Service

    ... for a new building, they made a far-sighted decision. Jackie Hirsh - a longtime congregation member with multiple sclerosis, who used a wheelchair - was appointed to serve on the congregation's architectural advisory committee. "Our community did ...

    Comment?

  18. Domestic Relations a " Alimony - " Wife's Ability to Work - " MSRead the original story

    Friday Jul 24 | South Carolina Lawyers Weekly

    Roof v. Steele Appealed from Lexington County Family Court S.C. App. Holding: Although the plaintiff-wife, who suffers from multiple sclerosis, works full time - earning less than minimum wage - in the frame shop she co-owns, this does not mean she would be able ... You may have reached this page due to new security upgrades that have been implemented regarding multiple user logins.

    Comment?

  19. Biogen cuts 2015 profit outlook; shares plungeRead the original story w/Photo

    Friday Jul 24 | Lowell Sun

    Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple-sclerosis drugs, Tecfidera, slow down. The biotech now expects 2015 adjusted earnings in the range of $15.50 to $15.95 per share.

    Comment?

  20. Biogen is crashing after cutting the outlook for its blockbuster drugRead the original story w/Photo

    Friday Jul 24 | Albany Times Union

    Biogen shares fell more than 19% on Friday after quarterly earnings results that beat on profits but missed on revenues. Also, the biotech giant lowered its forecast for full-year earnings and sales because it doesn't expect Tecfidera, its key multiple sclerosis drug, to grow as expected.

    Comment?